Drug-resistant malaria poses growing challenge to treatment and elimination efforts
Antimalarial drug resistance in India, particularly mutations to artemisinin-based therapies, poses a critical threat to malaria control and elimination efforts,say experts
360° Perspective Analysis
Deep-dive into Geography, Polity, Economy, History, Environment & Social dimensions — AI-powered, on-demand
Context
Despite a significant drop in global malaria incidence between 2000 and 2015, the trend has reversed over the past decade, rising by 8.5% since 2015, posing a challenge to global elimination goals. This resurgence is increasingly driven by the emergence of drug-resistant strains of the malaria parasite, particularly partial resistance to artemisinin-based combination therapies (ACTs). India, which has seen its malaria burden decline, faces unique challenges due to a high prevalence of Plasmodium vivax and the persistent threat of transmission in tribal and forest areas.
UPSC Perspectives
Governance
India has made significant progress in reducing its malaria burden, moving from the 's High Burden to the High Impact list, primarily through effective governance strategies like the test-track-treat approach and community-level interventions. The deployment of (ASHAs) for door-to-door screening and early diagnosis has been pivotal, especially in rural areas. However, this success is fragile. Transmission remains high in tribal and forested regions where healthcare access is limited, highlighting the challenge of ensuring equitable health service delivery. For UPSC, this underscores the importance of decentralized healthcare models and the role of frontline workers in disease control, aligning with the broader governance goal of achieving universal health coverage and the target of eliminating malaria by 2030.
Social
The emergence of drug-resistant malaria presents a significant public health challenge, directly impacting vulnerable populations. Resistance is fueled by factors such as poor adherence to treatment protocols, incorrect use of medicines, and the circulation of substandard drugs. India faces a unique epidemiological challenge with its malaria case mix, where Plasmodium vivax accounts for nearly 43% of cases. Unlike P. falciparum, which causes more severe disease, P. vivax can lie dormant in the liver (as hypnozoites) and cause relapses, complicating treatment and enabling silent transmission. The use of specific drugs like primaquine is crucial to target these dormant forms. Understanding the specific challenges posed by different parasite strains is crucial for developing targeted public health interventions and addressing health inequalities in regions with persistent transmission.
Scientific/Environmental
The scientific challenge of malaria control is compounded by environmental factors, particularly climate change and vector adaptation. The spread of Anopheles stephensi, a mosquito species that has adapted to urban environments, along with shifting climate patterns, threatens to expand malaria transmission zones. Genetically, the emergence of partial resistance to artemisinin—the core component of first-line treatments—is linked to mutations in the parasite's kelch13 (K13) gene. To counter this, scientists are exploring triple ACT combinations (pairing artemisinin with two partner drugs) and developing new classes of antimalarials. For the UPSC exam, this highlights the intersection of climate change with public health, the critical need for molecular surveillance to monitor genetic mutations like K13, and the necessity of ongoing scientific research to stay ahead of evolving pathogen resistance.